Weekly Digest – June 2025 Weekly Digest – June 2025 24 June 2025: MediLink announces YL201 granted Breakthrough Therapy Designation by FDA The U.S. FDA has granted Breakthrough Therapy Designation to YL201, a B7H3-targeted ADC developed by MediLink Therapeutics, for […]
Weekly Digest – June 2025 Weekly Digest – June 2025 25 June 2025: Huadong Medicine’s FGFR2b target ADC innovative drug HDM2020 China IND was approved by the NMPA Zhongmei Huadong, a subsidiary of Huadong Pharmaceutical, received NMPA approval to initiate […]
Weekly Digest – June 2025 Weekly Digest – June 2025 24 June 2025: Dong-A ST files IND for Phase 1 clinical trial of ADC candidate for cancer Dong-A ST’s ADC subsidiary, Aptis, has submitted an IND application in South Korea […]
